Notice of Proposed Sale · 144
Tectonic Therapeutic, Inc.
TECXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- TECTONIC THERAPEUTIC, INC.
- Issuer CIK
- 0001681087
- SEC file number
- 001-38537
- Phone
- (339) 666-3320
- Person for whose account securities are to be sold
- TERRANCE MCGUIRE
- Relationships to issuer
- Former Director
- Street
- 490 ARSENAL WAY
- Street (continued)
- SUITE 200
- City
- WATERTOWN
- State / country code
- MA
- Postal code
- 02472
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 7,513 | 276,718.06 | 19,549,366 | 08/27/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/27/2026 | Stock Option Exercise | Issuer | 7,513 | N | 08/27/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| TERRANCE MCGUIRE | Common | 08/21/2026 | 10,200 | 383,670.96 |
Seller — prior-sale row 1, entry 1
- Name
- TERRANCE MCGUIRE
- Street
- 490 ARSENAL WAY
- Street (continued)
- SUITE 200
- City
- WATERTOWN
- State / country code
- MA
- Postal code
- 02472
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/27/2026
- Signed
- /s/ TERRANCE GERARD MCGUIRE
Company context
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit https://tectonictx.com/ and follow us on LinkedIn.